Amendment: SEC Form SC 13G/A filed by NextCure Inc.

$NXTC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $NXTC alert in real time by email
SC 13G/A 1 nextcure-sc13ga_093024.htm AMENDMENT TO SCHEDULE 13G
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

NextCure, Inc.


(Name of Issuer)

 

Common Stock, par value $0.001 per share


(Title of Class of Securities)

 

65343E 108


(CUSIP Number)

 

Michael Hirschberg, Esq.
Reitler Kailas & Rosenblatt LLP
885 Third Avenue, 20th Floor
New York, NY 10022


(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

September 30, 2024


(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐  Rule 13d-1(b)
☒  Rule 13d-1(c)
☐  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 65343E 108   13G   Page 2 of 7 Pages
         
1.  

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Affinity Healthcare Fund, LP (EIN 82-1629802)

   
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ☐
(b)    ☐
   
3.   SEC USE ONLY
 
   
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
   
         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
  5.  

SOLE VOTING POWER

 

  6.  

SHARED VOTING POWER
2,302,598 shares of Common Stock

 

  7.  

SOLE DISPOSITIVE POWER
 0

 

  8.  

SHARED DISPOSITIVE POWER
2,302,598 shares of Common Stock

 

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,302,598 shares of Common Stock

   
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐
   
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.22%

   
12.  

TYPE OF REPORTING PERSON (see instructions)

 

PN

   

 

 

 

 

CUSIP No. 65343E 108   13G   Page 3 of 7 Pages
         
1.  

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Affinity Asset Advisors, LLC (EIN 82-1567490)

   
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)     ☐
(b)     ☐
   
3.   SEC USE ONLY
 
   
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware

   
         
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

SOLE VOTING POWER
0

 

  6.  

SHARED VOTING POWER

 

2,302,598 shares of Common Stock

 

  7.  

SOLE DISPOSITIVE POWER
0

 

  8.  

SHARED DISPOSITIVE POWER

 

2,302,598 shares of Common Stock 

 

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,302,598 shares of Common Stock
   
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐
   
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.22%
   
12.  

TYPE OF REPORTING PERSON (see instructions)

 

IA

   
         

 

 

 

 

CUSIP No. 65343E 108   13G   Page 4 of 7 Pages

 

Item 1.

 

  (a)

Name of Issuer:

 

NextCure, Inc.

     
  (b)

Address of Issuer’s Principal Executive Offices:

 

9000 Virginia Manor Road
Suite 200

Beltsville, MD 20705

 

Item 2.

 

  (a)

Name of Persons Filing:

 

Affinity Healthcare Fund, LP
Affinity Asset Advisors, LLC

     
  (b)

Address of Principal Business Office or, if None, Residence:

 

767 Third Avenue

New York, NY 10017

     
  (c)

Citizenship:

 

Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware

     
  (d)

Title of Class of Securities:

 

Common Stock, par value $0.001 per share

     
  (e)

CUSIP Number:

 

65343E 108

 

 

 

 

CUSIP No. 65343E 108   13G   Page 5 of 7 Pages

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
  (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
       
  (k)

Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

 

 

 

CUSIP No. 65343E 108   13G   Page 6 of 7 Pages

 

Item 4.  Ownership.

 

Affinity Asset Advisors, LLC (the “Advisor”) is the investment manager of Affinity Healthcare Fund, LP (the “Fund”) and exercises investment discretion with regard to the securities reported herein. As of November 13, 2024, the Fund beneficially owned an aggregate of 2,302,598 shares of Common Stock of the Issuer, or 8.22% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of such 2,302,598 shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of 2,302,598 shares of Common Stock of the Issuer.

 

The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 28,006,684 shares of Common Stock of the Issuer outstanding as of November 1, 2024 as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.

 

Item 5.  Ownership of Five Percent or Less of a Class.

 

Not Applicable

 

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable 

 

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not Applicable

 

Item 8.  Identification and Classification of Members of the Group.

 

Not Applicable 

 

Item 9.  Notice of Dissolution of Group.

 

Not Applicable 

 

Item 10.  Certification.

 

By signing below, we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

CUSIP No. 65343E 108   13G   Page 7 of 7 Pages

 

 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  November 13, 2024
  Date
   
  Affinity Healthcare Fund, LP
   
  By: /s/ Michael Cho
  Signature
   
   
  AFFINITY ASSET ADVISORS, LLC
   
  By: /s/ Michael Cho
  Signature

 

 

Get the next $NXTC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NXTC

DatePrice TargetRatingAnalyst
11/4/2022Buy → Neutral
Ladenburg Thalmann
3/1/2022$16.00Buy
Ladenburg Thalmann
11/5/2021$30.00 → $14.00Buy
Needham
More analyst ratings

$NXTC
Press Releases

Fastest customizable press release news feed in the world

See more
  • NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

    BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative m

    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • NextCure Provides Business Update and Reports Full Year 2024 Financial Results

    Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results. "In 2024 we reprioritized our resources to advance our antibody-drug conjugate ("ADC") program and recently completed cohor

    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

    BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. "Dosing the first patient in the LNCB74 Phase 1 study is a significant milestone for NextCure as we continue to advance our B7-H4 ADC program," said Udayan Guha, M.D., Ph.D., NextCure's Senior Vice President, Clinical & Translational Development. "We look forward to establishing the safe

    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NXTC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NXTC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NXTC
SEC Filings

See more

$NXTC
Leadership Updates

Live Leadership Updates

See more
  • NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

    BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

    BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

    BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NXTC
Financials

Live finance-specific insights

See more
  • NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

    BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NXTC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more